- Preparation methods of 2-[(2-benzothiazolylmethyl)thio]-6-ethoxybenzothiazole and intermediates thereof
-
The invention provides a preparation method of 2-[(2-benzothiazolylmethyl)thio]-6-ethoxybenzothiazole. The method includes reacting a compound (II) and a compound (III) in a solvent under an alkalinecondition with or without a catalyst to obtain a compound (I) that is the 2-[(2-benzothiazolylmethyl)thio]-6-ethoxybenzothiazole. The invention further provides a preparation method of the compound (II), including reacting a compound (IV) with a nitrosation agent and a copper agent in order in a solvent. The invention further provides a preparation method of the compound (III), including reactinga compound (V) with a sulfurizing agent in a solvent to obtain the compound (III). According to the methods, raw materials are cheap and easily available or easy to prepare, reaction conditions are mild, and selectivity and yields are high. The intermediates and a product are purified through crystallization instead of column chromatography and the methods are suitable for industrialization.
- -
-
Page/Page column 7-14
(2018/12/02)
-
- Substrate Fragmentation for the Design of M. tuberculosis CYP121 Inhibitors
-
The cyclo-dipeptide substrates of the essential M. tuberculosis (Mtb) enzyme CYP121 were deconstructed into their component fragments and screened against the enzyme. A number of hits were identified, one of which exhibited an unexpected inhibitor-like binding mode. The inhibitory pharmacophore was elucidated, and fragment binding affinity was rapidly improved by synthetic elaboration guided by the structures of CYP121 substrates. The resulting inhibitors have low micromolar affinity, good predicted physicochemical properties and selectivity for CYP121 over other Mtb P450s. Spectroscopic characterisation of the inhibitors′ binding mode provides insight into the effect of weak nitrogen-donor ligands on the P450 heme, an improved understanding of factors governing CYP121–ligand recognition and speculation into the biological role of the enzyme for Mtb.
- Kavanagh, Madeline E.,Gray, Janine L.,Gilbert, Sophie H.,Coyne, Anthony G.,McLean, Kirsty J.,Davis, Holly J.,Munro, Andrew W.,Abell, Chris
-
supporting information
p. 1924 - 1935
(2016/10/06)
-
- Substituted organosulfur compounds and methods of using thereof
-
The present invention provides substituted di-, tri-, tetra- and penta-sulfide compounds and compositions, and methods of using the same for the treatment and/or prevention of a cell proliferative disorder. The present invention also provides methods for preparing trisulfide compounds and compositions.
- -
-
Page/Page column 9
(2008/06/13)
-
- Synthesis and study of 2-(2-thienyl)benzazole type fluorophores
-
Reaction of 2-(mercaptomethyl)benzazoles 2a-c or isothiouronium salt 4 with acetyleneketone 5 or β-halogeno-α,β-unsaturated aldehyde 7 gives highly fluorescent heterocycles 6a-c or 8a-d. The fluorescence properties of these compounds and their aromatised
- Kalai, Tamas,Jeko, Jozsef,Osz, Erzsebet,Hideg, Kalman
-
p. 1433 - 1442
(2007/10/03)
-
- Synthesis and Biological Activity of trans-(+/-)-N-Methyl-2-(3-pirydyl)-2-tetrahydrothiopyrancarbothioamide 1-Oxide (RP 49356) and Analogues: A New Class of Potassium Channel Opener
-
The synthesis and biological activity of trans-(+/-)-N-methyl-2-(3-pyridyl)-2-tetrahydrothiopyrancarbothioamide 1-oxide (8a, RP 49356) and analoques is reported.These compounds constitute a new structural class of K+-channel opener.The effects of changes in the pyridyl group, thioamide, and thiane ring on in vitro K+-channel opening activity are discussed.A 3-pyridyl or 3-quinolyl group, a small N-alkyl thioamide function, and a thiane oxide ring, in which the sulfoxide is in a trans relationship to thioamide, are preferred for activity.Selected compounds were tested intravenously in the normotensive anaesthetized rat for hypotensive effects, and the activities reflect their in vitro K+-channel opening activity.This led to further evaluation of compound 8a and the selection of the (-)-enantiomer 8b (RP 52891) for development as an antihypertensive and antianginal agent.
- Brown, Thomas J.,Chapman, Robert F.,Cook, David C.,Hart, Terance W.,McLay, Iain M.,et al.
-
p. 3613 - 3624
(2007/10/02)
-